参考文献: [1]CAR T-cell therapy for solid tumors. Lancet Oncol 2021; DOI: 10.1016/S1470-2045(21)00353-3. [2]https://endpts.com/exclusive-carl-junes-tmunity-encounters-a-lethal-roadblock-as-2-patient-deaths-derail-lead-trial-raise-red-flag-forcing-a-rethink-of-car-t-for-solid-tumor...
参考文献: [1]CAR T-cell therapy for solid tumors. Lancet Oncol 2021; DOI: 10.1016/S1470-2045(21)00353-3. [2]https://endpts.com/exclusive-carl-junes-tmunity-encounters-a-lethal-roadblock-as-2-patient-deaths-derail-lead-trial-...
CAR-T cell performance: how to improve their persistence? Front. Immunol. 13, 878209 (2022). CAS PubMed PubMed Central Google Scholar Drougkas, K. et al. Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end? J. Cancer Res...
Tumor-associated antigen heterogeneity, inefficient CAR-T cell trafficking and the immunosuppressive tumor microenvironment are considered as the most pivotal roadblocks in solid tumor CAR-T cell therapy. Materials and methods We reviewed the relevant literature/clinical trials for CAR-T cell immunotherapy...
Developing a CAR T cell therapy for solid tumors is particularly challenging because the therapy needs to first reach the solid tumor and then survive in a harsh microenvironment that is filled with cancer cells and other cells that prevent attack by the CART cells. But Priceman and his team ...
CARs are recombinant receptors for cell surface antigen redirected the specificity and activity of blood T lymphocytes and other types of the immune cells [2]. The rapid establishment of tumor-targeted T cells, elimination of obstacles, and augmentative kinetics of active immunization are noticed as...
1)The Next Frontier of CAR T-Cell Therapy: Solid Tumors 2)Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas,” Clin Cancer Res, 5:985–90, 1999. 3)C.E. Brown et al., “Bioactivity ...
for solid cancers. A good clinical outcome depends on several parameters: (1) choice of the target epitope; (2) CAR architecture; (3) CAR-T cell doses, frequencies and way of administration of CAR-T cells; (4) efficient tumor homing and long-term survival in the tumor environment; (5...
Adoptive cell therapy of solid tumors with reprogrammed T cells can be considered the “next generation” of cancer hallmarks. CAR-T cells fail to be as effective as in liquid tumors for the inability to reach and survive in the microenvironment surround
CAR-T (Chimeric Antigen Receptor T-Cell Immunotherapy),即嵌合抗原受体T细胞免疫疗法。该疗法是一种出现了很多年但近几年才被改良,并使用到临床中的新型细胞疗法。在急性白血病和非霍奇金淋巴瘤的治疗上有着显著的疗效,被认为是最有前景的肿瘤治疗方式之一。正如所有的技术一样,CAR-T技术也经历一个漫长的演化过程...